Table 1—

Subject characteristics at the start of and after 12 weeks of treatment

Soy
Placebo
Treatment difference (P value)
Baseline (n = 32)12 weeks (n = 32)% ChangeBaseline (n = 32)12 weeks (n = 32)% Change
Weight (kg)81.2 ± 13.181.7 ± 12.7+0.77 ± 1.8181.6 ± 13.181.7 ± 13.1+0.19 ± 1.910.369
Fasting glucose (mmol/l)7.29 ± 1.497.37 ± 1.63+1.14 ± 10.87.23 ± 1.377.57 ± 1.93+4.31 ± 12.70.340
HbA1c (%)6.83 ± 0.646.78 ± 0.61−0.64 ± 3.196.82 ± 0.666.88 ± 0.59+1.08 ± 3.900.048
Fasting insulin (μlU/ml)16.7 ± 8.1314.5 ± 6.58−8.09 ± 21.915.5 ± 7.2617.3 ± 10.7+9.92 ± 29.10.006
HOMA-IR5.54 ± 3.404.94 ± 2.94−6.47 ± 27.75.14 ± 3.046.09 ± 4.82+14.7 ± 32.10.003
Cholesterol (mmol/l), n = 31*5.78 ± 1.025.52 ± 0.92−4.07 ± 8.135.62 ± 1.055.75 ± 1.07+2.83 ± 8.700.004
LDL cholesterol (mmol/l), n = 313.63 ± 0.913.35 ± 0.85−7.09 ± 12.73.47 ± 1.063.62 ± 1.07+5.35 ± 15.20.001
HDL cholesterol (mmol/l) n = 31*1.32 ± 0.331.32 ± 0.34+0.69 ± 10.11.30 ± 0.301.31 ± 0.30+1.29 ± 8.780.787
Cholesterol/HDL ratio, n = 31*4.64 ± 1.374.43 ± 1.26−3.89 ± 11.74.54 ± 1.354.61 ± 1.35+2.23 ± 12.10.015
Triglycerides (mmol/l), n = 31*2.20 ± 1.212.01 ± 1.03−1.58 ± 31.22.18 ± 1.622.19 ± 1.51+2.81 ± 24.90.624
Systolic blood pressure, n = 29146.9 ± 18.8144.7 ± 14.6−0.76 ± 9.63147.2 ± 15.2149.5 ± 17.2+1.65 ± 7.460.325
Diastolic blood pressure, n = 2981.5 ± 8.7880.7 ± 8.78−0.41 ± 10.482.6 ± 7.882.2 ± 8.73−0.23 ± 8.830.991
  • Data are means ± SD. All serum results are obtained from fasting variables. % change, percent difference compared with baseline. P value was calculated using Wilcoxon’s signed-rank test.

  • *

    * One subject was removed from the analysis of the lipid effects because they were started on a statin drug during the trial period;

  • three subjects were removed from the analysis of the effects on blood pressure because their medications were changed during the trial period.